SEC Looking at Auditors’ Crypto Work; Worried That Crypto Companies Overstating Auditors’ Limited Work

-Wall Street Journal

-Wall Street Journal

Total
0
Shares
Related Posts
Read More

Akoya Biosciences Announces Preliminary Financial Results For Q4 And FY23 And Provides 2024 Outlook; Sees Q4 Revenue $25.5M-$26.5M Vs $26.28M Est.; FY23 Revenue $95.6M-$96.6M Vs $96.6M Est.; Expects FY24 Revenue To Grow 20%+

Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2023, and projected year end 2023

AKYA